Four Seasons Before Lunch Gauteng (Pretoria)

 I have lived in Pretoria for half my life, but even at almost 50, l still am not ready for mornings like this . I step out of  home in the morning at 7 a.m., greeted by a warm, gentle breeze and sunshine so golden it felt like summer had arrived overnight. The sky was clear; the jacaranda trees glowed purple; the air smelled of warmth and possibility. “Perfect day,” l muttered, locking his door. By the time l drive out—five minutes later—the sky starts to be darkened. A cold wind came crawling in from nowhere, sweeping dust across the pavement. The temperature dropped so suddenly that  l have  to switch the heater for warmth. Laughing. “Ah, Pretoria… you never disappoint.” Halfway to the office, the heavens opened. Not soft rain— a storm . Sheets of water hammered the road, street gutters overflowed instantly, and distant thunder rolled like a grumpy giant waking up too early. People scattered, hiding under bus shelters already too full.  “Ten minutes ago...

Israeli study finds 94% drop in symptomatic COVID-19 cases with Pfizer vaccine By Reuters• 14 February 2021 A Pfizer vaccine will be rolled out to every state i

 

JERUSALEM, Feb 14 (Reuters) - Israel's largest healthcare provider on Sunday reported a 94% drop in symptomatic COVID-19 infections among 600,000 people who received two doses of the Pfizer's vaccine in the country's biggest study to date.

Health maintenance organization (HMO) Clalit, which covers more than half of all Israelis, said the same group was also 92% less likely to develop severe illness from the virus.

The comparison was against a group of the same size, with matching medical histories, who had not received the vaccine.

“It shows unequivocally that Pfizer’s coronavirus vaccine is extremely effective in the real world a week after the second dose, just as it was found to be in the clinical study,” said Ran Balicer, Clalit’s chief innovation officer.

He added that the data indicates the Pfizer vaccine, which was developed in partnership with Germany’s BioNTech, is even more effective two weeks or more after the second shot.

Researchers at the Weizmann Institute of Science, who have been tabulating national data, said on Sunday that a sharp decline in hospitalisation and serious illness identified earlier among the first age group to be vaccinated – aged 60 or older – was seen for the first time in those aged 55 and older.

Hospitalisations and serious illness were still rising in younger groups who began vaccinations weeks later.

Israel has been conducting a rapid vaccine rollout and its database offers insights into vaccine effectiveness and at what point countries might attain herd immunity. (Reporting by Ari Rabinovitch and Maayan Lubell Editing by David Goodman)


Comments

Popular posts from this blog

MultiChoice’s BEE scheme trying to find 22 000 shareholders who are missing out on millions

Fighting Drug addiction

Ultra-Widebody Volkswagen Bus "Volkswide" Looks Like a Porsche Racing Van